NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report issued on Saturday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Trading Up 0.7 %

Shares of NURO opened at $4.45 on Friday. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $4.73. The company has a market cap of $9.17 million, a PE ratio of -0.97 and a beta of 1.82. The stock has a 50-day moving average price of $4.39 and a 200-day moving average price of $4.16.

Institutional Trading of NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC purchased a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned approximately 0.57% of NeuroMetrix as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 19.40% of the company’s stock.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.